Person: SARIHAN, SÜREYYA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
SARIHAN
First Name
SÜREYYA
Name
7 results
Search Results
Now showing 1 - 7 of 7
Publication Radiotherapy in patients with trachea tumours: A retrospective study and literature review(Kare Yayınevi, 2020-01-01) Sarihan, Süreyya; Bayram, Ahmet Sami; Melek, Hüseyin; Gebitekin, Cengiz; SARIHAN, SÜREYYA; BAYRAM, AHMET SAMİ; MELEK, HÜSEYİN; GEBİTEKİN, CENGİZ; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; 0000-0003-4816-5798; 0000-0003-0684-0900; AAE-1069-2022; AAI-5039-2021; JCE-0097-2023; ABB-7580-2020; AAH-4970-2021OBJECTIVEIn this study, we aimed to evaluate our patients with tracheal tumours treated with primary or adjuvant radiotherapy (RT) and to review the current literature on the subject.METHODSBetween 1998 and 2017, eight patients underwent RT. Their median age was 37 years (15-53). The diagnosis was adenoid cystic carcinoma in five patients, squamous cell carcinoma in three patients and mucoepidermoid carcinoma in one patient. Resection type was R0 (1), R1 (4), R2 (1), and biopsy (2). The median tumour size was 2.6 cm (2-5). Median 59.4 Gy RT (32.4-66.6) was given, and weekly cisplatin was administered to four patients concomitantly.RESULTSWith a median follow-up of 85 months (4-189), five patients were alive. The 5-year overall and disease-free survival rates were 83% and 67%, respectively. There was no local recurrence in any patient. In one patient who had a complete response with curative chemo-RT, dilatation was performed five times in 10 years because tracheal stenosis developed at 60 months.CONCLUSIONTrachea tumours are rare, and the primary treatment is surgery. Adjuvant RT is controversial in R0 cases. In unresectable cases, RT is the primary treatment modality. We believe that our treatment results will contribute to the literature on the subject.Publication Relationship between pet/ct response and survival in patients with non-small-cell lung cancer treated with definitive chemoradiotherapy(Akad Doktorlar Yayınevi, 2021-01-01) Sarıhan, Süreyya; Bilgin, Gökçe Beige; Sığırlı, Deniz; SARIHAN, SÜREYYA; Bilgin, Gökçe Beige; SIĞIRLI, DENİZ; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Nükleer Tıp Anabilim Dalı; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı; 0000-0003-4816-5798; AAH-4970-2021; EMG-1218-2022; AAA-7472-2021We aimed to evaluate the relationship between PET/CT response and survival in patients with non-small cell lung cancer (NSCLC) treated with curative chemoradiotherapy. Between January and December 2012, 51 patients were treated. The median age was 61 (29-79) and the M/F ratio was 46/5. Eighty two percent of the cases were stage III and 53% were squamous cell carcinoma. Median 6300 cGy (4860-7525) radiotherapy delivered and 92% of patients received chemotherapy. The median follow-up was 27 months (7-96 months) in November 2019. The objective response was 71% with CT at 1 month and 76% with PET/CT at 3 months. There was a significant correlation between response-1 and response-3 (p< 0.001). Tumor SUVmean3 < 2.81, SUVmax change >= 70% was associated with response-1 (p< 0.05). The median and 5-year overall (OS) and progression-free (PFS) survival rates were 54 months, 40% and 35 months, 38%, respectively. In Cox model, for each 1 unit increase, SUVmeanbase (HR: 1.18, 95% CI: 1.01-1.38) and SUVmean3 (HR: 2.65, 95% CI: 1.24-5.66) were found unfavorable factors for OS, whereas SUVmean3 (HR: 2.01, 95% CI: 1.02-3.93) was also found to be a poor prognostic factor for PFS. PET/CT parameters can be used as useful markers for prognosis in patients with NSCLC undergoing curative chemoradiotherapy. It is believed that early assessment during and after treatment can be advantageous in terms of treatment modification.Publication The survival effect of resection of cranial metastatic lesions in patients with lung cancer(Elsevier Science, 2015-09-01) Deligönül, Adem; Taşkapılıoğlu, Özgür; Melek, Hüseyin; Bekar, Ahmet; Çetinkaya, Gamze; Sarihan, Süreyya; Bayram, Ahmet Sami; Gebitekin, Cengiz; Evrensel, Türkkan; DELİGÖNÜL, ADEM; TAŞKAPILIOĞLU, MEVLÜT ÖZGÜR; MELEK, HÜSEYİN; BEKAR, AHMET; Çetinkaya, Gamze; SARIHAN, SÜREYYA; BAYRAM, AHMET SAMİ; GEBİTEKİN, CENGİZ; EVRENSEL, TÜRKKAN; Uludağ Üniversitesi/Tıp Fakültesi/İç Hastalıkları Anabilim Dalı/Tıbbi Onkoloji Bilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Beyin ve Sinir Cerrahisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; 0000-0001-5472-9065; 0000-0003-4816-5798; 0000-0003-0684-0900; AAI-5039-2021; ABX-9081-2022; AAH-4970-2021; AAE-1069-2022; JDW-2654-2023; AAJ-1027-2021; JCE-0097-2023; ABB-8161-2020; ABB-7580-2020Publication Dosimetric comparison of free-breathing versus respiratory motion-managed radiotherapy via four-dimensional computed tomography-based volumetric-modulated arctherapy for lung cancer(Elsevier, 2023-11-29) Sarıhan, Süreyya; Tunç, Sema G.; Kahraman, Arda; İrem, Z. K.; SARIHAN, SÜREYYA; TUNÇ, SEMA; Kahraman, Arda; İrem, Z. K.; Bursa Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı; 0000-0003-4816-5798; 0000-0003-0150-8052; AAH-4970-2021; GYZ-7605-2022; CXV-2013-2022; IDR-0016-2023; 0000-0003-4697-8234Purpose. - The aim of this study is to use respiratory motion-managed radiotherapy (RT) to reduce side effects and to compare dosimetric factors with free-breathing planning in patients with lung cancer.Materials and methods. - Simulation images were obtained in 10 respiratory phases with free breathing using four-dimensional computed tomography (4D-CT) scanner. Planning target volume (PTV) was cre-ated with 5 mm margins in each direction of the internal target volume delineated using the maximum intensity projection. A volumetric arc treatment (VMAT) plan was created so that the prescribed dose would cover 98% of the PTV. Target volumes for the free-breathing VMAT plan were created according to ICRU Reports 62 and the same prescribed dose was used.Results. - Patients were evaluated during January 2020. Median 63 Gy (59.4-64) RT was administered. Median PTV volumes were 173.53 and 494.50 cm3 (P = 0.008) and dose covering 95% of PTV volume was 62.97 and 60.51 Gy (P = 0.13) in 4D-CT based and free-breathing VMAT plans, respectively. The mean and V50 heart dose was 6.03 Gy (vs. 10.36 Gy, P = 0.043) and 8.2% (vs. 33.9%, P = 0.007), and significantly lower in 4D-CT based VMAT plans and there was also found a non-significant reduction for other risky organ doses. Conclusion. - Ten patients treated with respiratory motion-managed RT with 4D-CT based VMAT tech-nique. It was observed that PTV did not increase, the target was covered with 95% accuracy, and with statistical significance in heart doses, all risky organ doses were found to be less.(c) 2023 Societe franc,aise de radiotherapie oncologique (SFRO). Published by Elsevier Masson SAS. All rights reserved.Publication Thymic tumors and results of radiotherapy(Via Medica, 2018-03-01) Sarıhan, Süreyya; Bayram, Ahmet Sami; Gebitekin, Cengiz; Yerci, Ömer; Sığırlı, Deniz; SARIHAN, SÜREYYA; BAYRAM, AHMET SAMİ; GEBİTEKİN, CENGİZ; YERCİ, ÖMER; SIĞIRLI, DENİZ; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Göğüs Cerrahisi Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.; Uludağ Üniversitesi/Tıp Fakültesi/Biyoistatistik Anabilim Dalı.; 0000-0003-4816-5798; 0000-0003-0684-0900; JCE-0097-2023; ABB-7580-2020; AAH-4970-2021; AAA-7472-2021; AAE-1069-2022Aim: The aim of this study was to evaluate thymic epithelial tumors (TETs) for treatment outcomes and prognostic factors on survival.Background: TETs are very rare neoplasms and multidisciplinary approach is recommended according to prognostic factors.Materials and methods: Between 1995 and 2013, 31 patients were treated with median 5400 cGy (range: 1620-6596 cGy) radiotherapy (RT). Eleven patients received adjuvant or concurrent chemotherapy. There were 25 thymomas, 4 thymic carcinomas and 2 thymic neuroendocrin carcinomas. According to Masaoka, staging and WHO classification, cases were divided to good (n: 10), moderate (n: 9) and poor (n: 12) prognostic risk groups. Survival was calculated from diagnosis.Results: In January 2016, 22 cases were alive with median 51.5 months (range: 2-170.5) follow-up. Recurrences were observed in 29% of patients in median 29.5 months (range: 6.5-105). Local control, mean overall (OS) and disease-free survival (DFS) rates were 86%, 119 and 116 months, respectively. There was a significant difference for RO vs. R+ resection (81% vs. 43%, p = 0.06, and 69% vs. 46%, p = 0.05), Masaoka stage I-II vs. III-IV (75% vs. 52%, p = 0.001, and 75% vs. 37%, p < 0.001), and also prognostic risk groups (100% vs. 89% vs. 48%, p = 0.003, and 100% vs. 87% vs. 27%, p = 0.004) in terms of 5-year OS and DFS, respectively.Conclusion: In our study, prognostic risk stratification was shown to be a significant predictor of survival. There is a need to investigate subgroups that may or may not benefit from adjuvant RT. (C) 2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.Publication Stereotactic body radiotherapy for primary and metastatic lung cancer, cyberknife-m6 experience(Elsevier Science Inc, 2022-09-01) Sarıhan, S.; SARIHAN, SÜREYYA; Tunç, S. G.; İrem, Z. K.; ÇELİK UZUNÇAKMAK, ZEYNEP İREM; Kahraman, A.; KAHRAMAN, AYŞEGÜL; Bursa Uludağ Üniversitesi/Tıp Fakültesi; 0000-0002-2597-1001Publication Lung cancer: Elective nodal irradiation(Kare, 2012-01-01) Sarıhan, Süreyya; SARIHAN, SÜREYYA; Uludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkoloji Anabilim Dalı; 0000-0003-4816-5798; AAH-4970-2021The goal of the treatment for lung cancer is to obtain local control, and as a result, to improve survival. In order to treat potentially subclinical disease, delivery of 40-50 Gy radiotherapy (RT) to the regional-nodal areas is designated as elective nodal irradiation (ENI). Increasing the volume of irradiated normal tissues with this approach leads to greater toxicity and prevents successful dose escalation. Advances in the staging of mediastinal disease and lower-than-expected elective nodal failure rates with involved nodal RT led to questions regarding the use of ENI, specifically, what is the target volume for postoperative irradiation? Restricted target volume usage with modem RT techniques has led to a negative effect on regional control due to inter- and intra-fraction motions, and it is questionable whether selective ENI is reasonable in curative treatment. This review evaluates the changes concerning the use of ENI over time.